Exelixis, Inc. $EXEL Shares Purchased by Lingohr Asset Management GmbH

Lingohr Asset Management GmbH raised its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 1,258.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 284,022 shares of the biotechnology company’s stock after purchasing an additional 263,121 shares during the period. Exelixis comprises approximately 2.8% of Lingohr Asset Management GmbH’s holdings, making the stock its 4th largest holding. Lingohr Asset Management GmbH owned about 0.11% of Exelixis worth $11,730,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Winnow Wealth LLC acquired a new stake in Exelixis in the third quarter valued at $1,017,000. Arizona State Retirement System increased its position in shares of Exelixis by 4.3% in the 3rd quarter. Arizona State Retirement System now owns 76,652 shares of the biotechnology company’s stock worth $3,166,000 after purchasing an additional 3,172 shares during the last quarter. Impact Partnership Wealth LLC raised its stake in shares of Exelixis by 17.3% in the 3rd quarter. Impact Partnership Wealth LLC now owns 9,788 shares of the biotechnology company’s stock valued at $404,000 after purchasing an additional 1,443 shares in the last quarter. Foundations Investment Advisors LLC acquired a new stake in shares of Exelixis in the 3rd quarter valued at about $322,000. Finally, Ruffer LLP lifted its position in shares of Exelixis by 7.1% during the third quarter. Ruffer LLP now owns 81,696 shares of the biotechnology company’s stock worth $3,374,000 after purchasing an additional 5,386 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Stock Performance

EXEL stock opened at $41.36 on Friday. Exelixis, Inc. has a 1 year low of $32.38 and a 1 year high of $49.62. The stock has a market capitalization of $11.09 billion, a price-to-earnings ratio of 17.45, a PEG ratio of 0.76 and a beta of 0.40. The stock’s fifty day moving average is $43.76 and its two-hundred day moving average is $41.06.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.10. The business had revenue of $597.76 million for the quarter, compared to analysts’ expectations of $590.04 million. Exelixis had a net margin of 29.63% and a return on equity of 31.06%. The company’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.47 EPS. As a group, analysts predict that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Wolfe Research began coverage on Exelixis in a research note on Tuesday, November 18th. They set a “peer perform” rating on the stock. Truist Financial set a $51.00 price target on Exelixis in a research report on Wednesday, January 14th. Oppenheimer restated a “market perform” rating and set a $36.00 price objective on shares of Exelixis in a research note on Wednesday, November 5th. Weiss Ratings reiterated a “buy (b)” rating on shares of Exelixis in a research note on Thursday, January 22nd. Finally, Guggenheim cut shares of Exelixis from a “buy” rating to a “neutral” rating in a report on Monday, November 3rd. Eleven equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $45.95.

Insider Activity

In related news, Director Mary C. Beckerle sold 24,622 shares of the stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $41.93, for a total value of $1,032,400.46. Following the completion of the transaction, the director directly owned 21,380 shares of the company’s stock, valued at $896,463.40. This represents a 53.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Patrick J. Haley sold 28,043 shares of Exelixis stock in a transaction on Friday, November 21st. The shares were sold at an average price of $42.58, for a total value of $1,194,070.94. Following the sale, the executive vice president directly owned 374,029 shares in the company, valued at $15,926,154.82. The trade was a 6.97% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 245,235 shares of company stock worth $10,490,600 over the last ninety days. 2.82% of the stock is owned by company insiders.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.